FindTrial
Sign In

NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HLA IDENTICAL SIBLING FOR METASTATIC SOFT TISSUE SARCOMAS

NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HLA IDENTICAL SIBLING FOR METASTATIC SOFT TISSUE SARCOMAS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-001035-32-IT
Enrollment
Unknown
Registered
2007-03-14
Start date
2004-05-13
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

METASTATIC SOFT TISSUE SARCOMAS MedDRA version: 9.1 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Interventions

Product Name: Thiotepa Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Thiotepa CAS Number: 52-24-4 Concentration unit: mg milligram(s) Concentration type: equal Concentra

Sponsors

ITALIAN SARCOMA GROUP
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026